OP Asset Management Ltd Invests $404,000 in Charles River Laboratories International, Inc. $CRL

OP Asset Management Ltd acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 2,340 shares of the medical research company’s stock, valued at approximately $404,000.

Other large investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its holdings in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at approximately $418,000. American Century Companies Inc. increased its stake in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares in the last quarter. Brown Advisory Inc. increased its stake in shares of Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays increased their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Mizuho set a $192.00 price objective on Charles River Laboratories International in a research note on Friday, May 8th. Finally, Morgan Stanley upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $185.00 to $220.00 in a research report on Wednesday, June 17th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Stock Up 0.5%

Shares of NYSE CRL opened at $226.61 on Wednesday. The firm has a market cap of $10.92 billion, a P/E ratio of -60.27, a price-to-earnings-growth ratio of 2.58 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $228.88. The firm’s 50 day moving average price is $178.79 and its 200 day moving average price is $183.83.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same period in the previous year, the firm posted $2.34 EPS. Charles River Laboratories International’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.